In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

Pharmacological properties

serratiopeptidase is a proteolytic enzyme isolated from the non-pathogenic intestinal bacterium serratia e15. serratiopeptidase has a fibrinolytic, anti-inflammatory decongestant effect. in addition to reducing the inflammatory process, serratiopeptidase reduces the severity of pain due to blocking the release of pain amines from inflamed tissues.

Serratiopeptidase binds in a 1: 1 ratio to α-2-macroglobulin in the blood, which masks its antigenicity, but retains enzymatic activity. Serratiopeptidase slowly passes into exudate in the focus of inflammation and gradually its level in the blood decreases. Serratiopeptidase reduces the dilatation of capillaries and controls their permeability by hydrolysis of bradykinin, histamine and serotonin. Serratiopeptidase blocks plasmin inhibitors, thereby contributing to its fibrinolytic activity. Due to the proteolysis of structural proteins of sputum, it improves its rheological properties and renders it pass away.

The enzymatic activity of the drug is 10 times higher than that of α-chymotrypsin. In the focus of chronic inflammation, serratiopeptidase helps reduce the level of mediators of inflammation and pain, hydrolyzes fibrin, preventing the formation of adhesions, improves microcirculation in the focus of chronic inflammation, which improves the bioavailability of antibiotics, NSAIDs and other drugs.

It does not significantly affect the proteins of a living organism, such as albumin, α- and γ-globulin. The drug does not break down fibrinogen, therefore, does not have a significant effect on blood coagulation processes.

Movinase penetrates well into the site of inflammation, lyses necrotic tissues and their decay products, reduces hyperemia and increases the penetration and activity of antibiotics. The drug reduces the viscosity of saliva and nasal secretions, thereby facilitating their removal.

Pharmacokinetics Movinase passes through the stomach unchanged and is absorbed in the intestine. WITHmax in blood plasma, it is reached after 1 h. Serratiopeptidase enters the bloodstream in an enzyme-active form, is also excreted in the active form with bile, and in small amounts it appears in the urine.


Surgery: sprains and tears of ligaments, fractures and dislocations, edema after plastic surgery.

Diseases of the upper respiratory tract: reduces the viscosity of sputum and facilitates its discharge from the respiratory tract.

Diseases of the ENT organs: facilitates the passage of the secretion of the sinuses.

Dermatology: acute inflammatory dermatoses.

Obstetrics and gynecology: hematomas, stagnation in the mammary glands.


The drug movinase is prescribed to adults at 10-20 mg after a meal. tablets should be swallowed without chewing, washed down with 1 glass of water. the maximum daily dose is 30 mg. the duration of the course of treatment depends on the course of the pathological process and is determined individually by the doctor.


Hypersensitivity to serratiopeptidase or other components of the drug. coagulation system disorders.

Side effects

In some cases, when using the drug, it may be noted: diarrhea, nausea, vomiting, anorexia, discomfort in the epigastric region.

In some cases, nosebleeds and sputum production with an admixture of blood, allergic reactions, skin rash, acute eosinophilic pneumonia.

If any adverse reactions occur, consult a doctor.

special instructions

Since the drug affects blood coagulation, it must be used with caution in patients with a threat of bleeding and a violation of blood coagulation time, as well as in patients taking anticoagulants.

In case of severe liver and kidney diseases, the drug is used with caution.

Use during pregnancy and lactation.Not recommended due to lack of clinical data.

Children. There is no data on the safety and effectiveness of the drug in children, so it is not used in this category of patients.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. Does not affect.


When using the drug simultaneously with anticoagulants, the severity of the action of the latter increases; accelerates the penetration of inflamed tissues of antibiotics and NSAIDs.


Symptoms: nausea, vomiting, anorexia, epigastric discomfort. in some cases, an admixture of blood in the sputum and bleeding.

Treatment: symptomatic therapy.

Storage conditions

In the original packaging at temperatures up to 25 ° C.

Tags: Serratiopeptidase